Every patient, every caregiver has a story to tell. Every day their courage and strength inspire us.
We are driven by our commitment to our patients and their care givers – they are our inspiration and at the heart of everything we do. Their stories are our stories, their journey is our journey. They motivate us to do better work, to make meaningful impact: at Cycle, every single patient matters.
Find out more about our incredible, inspirational patients here:
Patient Stories (For US Consumers)
Five-year-old Ethan has Hereditary Tyrosinemia Type 1 (HT-1). Like any family that has a child with this ultra-rare condition, the family have found Ethan’s diet and medication regime very demanding. Learn more about their journey.
When Alina’s parents learned she had HT-1, they were understandably concerned. Watch their story.
For full Safety Information and Prescribing Information please visit:
NITYR® (nitisinone) Tablets are approved in the USA, Australia and the Kingdom of Saudi Arabia in 2, 5 and 10 mg strengths and in the EU and Chile in 10 mg strength. Cycle Pharmaceuticals’ nitisinone products are also approved under a different name, NITISINONE TABLETS, in Canada in 2, 5, and 10 mg strengths. Registration conditions differ internationally.
NITYR® is a registered trademark of Cycle Pharmaceuticals Limited in the United States.